CLAIM AMENDMENTS

This listing of claims will replace all prior versions, and listing, of claims in the application:

1. (cancelled)

2. (cancelled)

3. (withdrawn) A formulation that is immunoneutral to the immune system of an individual and capable of solubilizing hydrophobic antigens.

4. (withdrawn) A formulation according to claim 3 where immunoneutral hydrophobic solvent is species specific Serum Albumin.

5. (withdrawn) A formulation according to claim 4 including an antigen for stimulation of the immune system.

6. (withdrawn) A formulation for antigen specific downregulation of inflammatory responses comprising at least two of the ingredients antigen and alum.

7. (withdrawn) A formulation according to claim 5 or 6, where the antigen is of at least one from the group of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glima38, GAD 65, GAD67, SOX13, Imogen 38, Sulfatide, MBP, MOG, Collagen II, 21-Ohase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.

8. (withdrawn) A kit for evaluation of lymphocyte reaction to antigen comprising a formulation according to claim 7.

9. (withdrawn) A therapeutic comprising a formulation according to claim 7.

10. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 1-100 micrograms per ml.

11. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 5-40 micrograms per ml.

12. (withdrawn) A therapeutic according to claim 9 where the subcutaneous administration of antigen for in vivo stimulation typically is between 0.1 micrograms per ml.

13. (withdrawn) A therapeutic according to claim 9 where intravenous administration of antigen for in vivo stimulation typically is between 0.1 - 5 mgs/kg.

14. (new) A method to determine an immunomodulatory therapy formulation for an autoimmune, allergy or cancer disorder using a specific antigen in a mammal with an autoimmune, allergy or cancer disorder and whose immune system gives a current response to said antigen, the method comprising the steps:

(a) exposing an antigen *in vitro* to the immune system of the mammal in an otherwise non-immunogenic formulation so as not to interfere with the current response of the immune system to said antigen, so as to evaluate the current immune response to said antigen *in vitro* and

(b) determining a therapeutic formulation for said antigen, said formulation being suitable for downregulating the autoimmune disease by means of immunomodulation of one of the following: (a) Th1 cytotoxic response, (b) Th2 humoral response, (c) mixed Th1/Th2 response.

15. (new) A method according to claim 14 wherein said non-immunogenic formulation is capable of solubilizing hydrophobic antigens.

16. (new) A method according to claim 14 wherein said non.immunogenic formulation comprises species specific Serum Albumin.

17. (new) A method according to claim 14 wherein said formulations comprise an antigen selected from the group consisting of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glima38, GAD 65, GAD67, SOX13, Imogen 38, Sulfatide, MBP, MOG, Collagen II, 21-Ohase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.

DRAWING AMENDMENTS

There are no amendments to the drawings.